Atherosclerosis plus最新文献

{"title":"ApoE [−/−] CA1-overexpressing knock-in mice aggravated atherosclerosis by increasing M1 macrophages","authors":"Jinbao Zong ,&nbsp;Changyuan Wang ,&nbsp;Hongji Zhou ,&nbsp;Yu Song ,&nbsp;Kehua Fang ,&nbsp;Xiaotian Chang","doi":"10.1016/j.athplu.2025.03.003","DOIUrl":"10.1016/j.athplu.2025.03.003","url":null,"abstract":"<div><h3>Background</h3><div>Carbonic anhydrase I (CA1) has been reported to be a diagnostic and therapeutic target for atherosclerosis (AS). This study aimed to verify the essential role of CA1 in AS progression in CA1-overexpressing mice.</div></div><div><h3>Methods</h3><div>A ApoE [−/−] CA1-overexpressing knock-in mouse model was constructed via CRISPR/Cas9-mediated genome engineering. AS was then induced in these transgenic mice via the administration of a high-fat diet, and a second group simultaneously received treatment with methazolamide (MTZ), a carbonic anhydrase inhibitor.</div></div><div><h3>Results</h3><div>Compared with ApoE [−/−] mice without CA1 overexpression, CA1-overexpressing mice had a greater average body weight, regardless of whether their treatment with MTZ or their AS induction status. Sudan IV, hematoxylin and eosin and Oil Red O staining revealed more plaques and fat deposits in the cardiac aortas of CA1-overexpressing mice than in those of ordinary ApoE−/− mice when AS was induced. Moreover, the atherogenic index; low-density lipoprotein, total cholesterol and triglyceride levels were significantly elevated, and high-density lipoprotein levels were declined in the peripheral blood of CA1-overexpressing mice than in that of ordinary ApoE [−/−] mice, regardless of whether these animals were induced to AS. Immunohistochemistry, <em>Von Kossa</em> staining and fluorescence immunohistochemistry revealed increases in CA1 expression, calcium deposition and M1 macrophages in the aortic tissues of CA1-overexpressing mice with AS. MTZ treatment significantly suppressed AS pathologies in the above experiments.</div></div><div><h3>Conclusion</h3><div>These findings revealed aggravated AS in ApoE [−/−] CA1-overexpressing mice and suggest that CA1 aggravates AS by increasing M1-type macrophages, a proinflammatory macrophage subtype.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"60 ","pages":"Pages 6-19"},"PeriodicalIF":1.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world management of hypercholesterolemia in patients after acute coronary syndrome in Greece","authors":"Despoina Massia ,&nbsp;Periklis Giovas ,&nbsp;Nikolaos Papadopoulos ,&nbsp;Georgios Katsimagklis ,&nbsp;Evangelos Pissimisis ,&nbsp;Sotirios Patsilinakos ,&nbsp;Evgenia Pappa ,&nbsp;Giannis Baltogiannis ,&nbsp;Nikolaos Kouremenos ,&nbsp;Christos Dontas ,&nbsp;Evangelos Liberopoulos","doi":"10.1016/j.athplu.2025.03.002","DOIUrl":"10.1016/j.athplu.2025.03.002","url":null,"abstract":"<div><h3>Background</h3><div>Prompt initiation of lipid-lowering therapy (LLT) following acute coronary syndrome (ACS) is crucial for preventing secondary cardiovascular events. However, there are gaps in clinical implementation of the 2019 ESC/EAS guideline-recommended low-density lipoprotein cholesterol (LDL-C) goal of &lt;55 mg/dL in patients post-ACS.</div></div><div><h3>Methods</h3><div>This multicenter, real-world, retrospective, 12-month study of adult patients in Greece hospitalized for ACS from September 2019 to November 2022 assessed the attainment of target LDL-C (&lt;55 mg/dL) during the first year post-ACS. Eligible patients had elevated LDL-C at hospitalization (&gt;130 mg/dL if LLT naïve; &gt;100 mg/dL if on statin monotherapy; &gt;70 mg/dL if on a statin plus ezetimibe) and ≥1 LDL-C measurement within 12 months post-ACS.</div></div><div><h3>Results</h3><div>Overall, 212 eligible patients of mean (SD) age 59.9 (±11.1) years were enrolled. Type 2 diabetes and hypertension were reported in 19.8 % (42/212) and 50.9 % (108/212) of patients, respectively. Median (Q1, Q3) LDL-C was 138.0 (106.5, 158.0) mg/dL at hospitalization (n = 212). In patients with LDL-C availability at 12 months posthospitalization (n = 197), median (Q1, Q3) LDL-C was 64.0 (53.0, 76.0) mg/dL, with 27.9 % of patients (55/197) attaining LDL-C &lt;55 mg/dL. Although 73.9 % of patients (199/212) were discharged from the hospital on statin monotherapy, 50 % of patients (106/212) were receiving statin-ezetimibe LLT and 1.4 % (3/212) were receiving statin-ezetimibe-PCSK9 inhibitor LLT 12 months posthospitalization.</div></div><div><h3>Conclusion</h3><div>LDL-C goal attainment is suboptimal in the first year after ACS hospitalization in Greece, indicating an unmet need to improve the treatment of patients with hypercholesterolemia during the post-ACS period by optimizing lipid management through earlier LLT intensification.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"60 ","pages":"Pages 20-26"},"PeriodicalIF":1.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A male patient with pseudoxanthoma elasticum caused by isodisomy of chromosome 16 containing a nonsense variant of the ABCC6 gene: A quarter-century treatment experience","authors":"Minoru Wakasa ,&nbsp;Chihiro Nakagawa ,&nbsp;Taka-aki Takamura ,&nbsp;Kosuke Fujibayashi ,&nbsp;Hironobu Akao ,&nbsp;Michihiko Kitayama ,&nbsp;Akira Shimizu ,&nbsp;Yo Niida ,&nbsp;Kouji Kajinami","doi":"10.1016/j.athplu.2025.03.001","DOIUrl":"10.1016/j.athplu.2025.03.001","url":null,"abstract":"<div><div>Pseudoxanthoma elasticum (PXE) is a rare autosomal recessive disorder characterized by fragmentation and calcification of the elastic fibers of the skin, eyes, and various arteries with highly variable clinical expression. PXE is predominantly caused by pathogenic variants of the <em>ABCC6</em> gene, which encodes the ABCC6 efflux transporter; however, the precise mechanism responsible for clinical manifestation remains unclear. We herein report the case of a male patient with PXE with premature coronary stenosis as his first presentation requiring catheter intervention, in association with typical ocular and skin lesions; the latter was confirmed histologically. A molecular analysis revealed an isodisomy of 6.8 Mb in the 16p13.11 region containing the nonsense mutation p.(Gln199Ter) in the <em>ABCC6</em> gene. We also describe the 25-year clinical course of this case, while focusing on cardiovascular lesions.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"60 ","pages":"Pages 1-5"},"PeriodicalIF":1.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143696213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HDL-replacement therapy: From traditional to emerging clinical applications","authors":"Cesare Riccardo Sirtori ,&nbsp;Giulia Cincotto ,&nbsp;Sofia Castiglione ,&nbsp;Chiara Pavanello","doi":"10.1016/j.athplu.2025.02.001","DOIUrl":"10.1016/j.athplu.2025.02.001","url":null,"abstract":"<div><div>The unique and multifaceted properties of high-density lipoproteins (HDL)—ranging from cholesterol efflux to anti-inflammatory, anti-oxidant, and immunomodulatory effects—have prompted their direct use, particularly in cardiovascular ischemic conditions.</div><div>Recent advances have extended the interest in HDL-based treatments to novel applications, from improving stent biocompatibility, to treatment of heart failure to central nervous system (CNS) disorders. Strategies to harness HDL's therapeutic potential have evolved from the direct use of isolated HDL in animal models to reconstituted HDL (rHDL) in humans. For these latter, the use of isolated apoA-I associated with different phospholipids has been the most frequent approach, also involving apparently beneficial mutants, such as the apo A-I Milano (AIM).</div><div>From the initial very promising results, particularly with this mutant in coronary patients, later studies have mostly been non-confirmatory, although issues such as possible inadequate dose/response and unexpected immunological properties have come to light. Most recently a study on isolated plasma HDL in coronary patients (AEGIS-II) provided overall negative findings, but a clear fall of major cardiovascular events was recorded when restricting analysis to hypercholesterolemic patients.</div><div>Emerging approaches, including gene therapy and plant-derived recombinant HDL formulations, hold promise for enhancing the accessibility and efficacy of HDL-based interventions. At this time, an improved approach to heart failure treatment also appears feasible, and a better understanding of the role played by HDL in the CNS may lead to significant improvements in the handling of some dramatic diseases at this level. While challenges persist, the evolving landscape of HDL replacement therapies offers hope for significant progress in addressing both cardiovascular and non-cardiovascular conditions.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 68-79"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model","authors":"Daisuke Kitano ,&nbsp;Suguru Migita ,&nbsp;Yuxin Li ,&nbsp;Yutaka Koyama ,&nbsp;Katsunori Fukumoto ,&nbsp;Sayaka Shimodai-Yamada ,&nbsp;Akira Onishi ,&nbsp;Daiichiro Fuchimoto ,&nbsp;Shunichi Suzuki ,&nbsp;Yoshiyuki Nakamura ,&nbsp;Atsushi Hirayama ,&nbsp;Hiroyuki Hao ,&nbsp;Yasuo Okumura","doi":"10.1016/j.athplu.2025.01.002","DOIUrl":"10.1016/j.athplu.2025.01.002","url":null,"abstract":"<div><h3>Background</h3><div>The combination of antiplatelet and antithrombotic drugs increases the risk of bleeding in patients with atrial fibrillation after coronary drug-eluting stent (DES) implantation. However, the appropriateness of direct-acting oral anticoagulant (DOAC) monotherapy at the time of stent implantation remains uncertain. The objective of this study was to evaluate the safety and efficacy of DOAC monotherapy, specifically using factor Xa inhibitors such as edoxaban, in a low-density lipoprotein receptor knockout (LDL-R^−/−) miniature pig model of human-like unstable coronary plaques compared to conventional dual-antiplatelet therapy (DAPT).</div></div><div><h3>Methods</h3><div>We evaluated the safety and efficacy of edoxaban monotherapy in the LDL-R^−/− pig model with human-like unstable coronary plaques induced by a high-cholesterol, high-fat diet. Animals underwent DES implantation, followed by four weeks of treatment with either edoxaban monotherapy (3 mg/kg/day) or the DAPT regimen (aspirin 100 mg/day and clopidogrel 75 mg/day). Outcomes were assessed by optical coherence tomography (OCT), virtual histology intravascular ultrasound (iMap-IVUS), and histology. Key endpoints included in-stent thrombus formation, neointimal thickness, and coronary plaque composition.</div></div><div><h3>Results</h3><div>Edoxaban monotherapy demonstrated a significantly thinner neointimal layer (120.0 [92.5–160.0] μm vs. 210.0 [180.0–240.0] μm, <em>p</em> &lt; 0.001) and smaller neointimal area (1.06 [0.82–1.46] mm² vs. 1.84 [1.61–2.24] mm², <em>p</em> &lt; 0.001) compared to DAPT. Neointimal coverage, fibrin deposition, and inflammatory cell infiltration were comparable between groups. No in-stent thrombi were observed in either group. iMap-IVUS findings indicated that edoxaban monotherapy significantly suppressed the increase in lipidic and necrotic plaque area while promoting fibrotic area expansion.</div></div><div><h3>Conclusions</h3><div>Edoxaban monotherapy demonstrated superior efficacy in suppressing neointimal hyperplasia and stabilizing coronary plaques compared to DAPT with equivalent safety in preventing in-stent thrombus formation. These results provide important preclinical evidence supporting the potential of DOAC monotherapy as an antithrombotic strategy after DES implantation and warrant further investigation in clinical trials.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 59-67"},"PeriodicalIF":1.4,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143263756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Inclisiran: Early LDL-C target achievement in a real-life population”","authors":"Francesco Briani ,&nbsp;Mauro Bagli ,&nbsp;Gabriele Venturi ,&nbsp;Francesco Bacchion ,&nbsp;Antonio Mugnolo","doi":"10.1016/j.athplu.2025.01.001","DOIUrl":"10.1016/j.athplu.2025.01.001","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with atherosclerotic cardiovascular diseases. Inclisiran, a small interfering RNA, has been observed to effectively and sustainably reduce LDL-C in large randomized controlled trials (RCTs); however, real-world data on its short-term efficacy and use are limited. This study aims to assess the efficacy and safety of inclisiran in a real-life population within one month from the first administration.</div></div><div><h3>Methods</h3><div>This observational, single-center, retrospective cohort study included patients affected by dyslipidemia who could not achieve their LDL-C target despite a maximum tolerated oral lipid-lowering therapy (LLT). 284 mg Inclisiran was subcutaneously administered. Blood samples were collected before the inclisiran administration and at week and one month afterward with the aim toevaluate achievement of LDL-C targets at these time intervals (primary endpoint) and reduction in LDL-C levels (secondary endpoint).</div></div><div><h3>Results</h3><div>From September 2022 to December 2023, inclisiran was administered to 33 patients at Mater Salutis Hospital. After exclusion of two patients due to statin therapy modification or discontinuation during follow-up, a final number of 31 patients were included. At a median follow-up of 32 (IQ_1-3 30–37) days, 21 (67.7 %) patients reached their LDL-C target (primary endpoint). At 7 days, LDL-C mean value decreased from 123.6 ± 42.1 mg/dl to 97.9 ± 53.6 mg/dl, (p &lt; 0.001), with a 29.9 ± 20.6 % reduction. At 32 days, LDL-C mean value declined to 58.5 ± 42.8 mg/dl (p &lt; 0.001), with a 56.9 ± 20.9 % reduction.</div></div><div><h3>Conclusion</h3><div>In a real-life single center population, inclisiran safely led to LDL-C target achievement within one month. Significantly reduction of LDL-C levels were already present in the early days after the first administration.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 54-58"},"PeriodicalIF":1.4,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143263754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9","authors":"Marcella Palumbo ,&nbsp;Martina Ugolotti ,&nbsp;Francesca Zimetti ,&nbsp;Maria Pia Adorni","doi":"10.1016/j.athplu.2024.12.004","DOIUrl":"10.1016/j.athplu.2024.12.004","url":null,"abstract":"<div><div>A large body of evidence has shown that modulation of the nuclear receptors peroxisome proliferator-activated receptors (PPARs), the liver X receptors (LXRs), the proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory processes by natural compounds has hypolipidemic and anti-atherosclerotic effects. These beneficial outcomes are certainly related to the crucial function of these targets in maintaining cholesterol homeostasis and regulating systemic inflammation. Currently, the therapeutic scenario for cardiovascular diseases (CVD) offers a plethora of widely validated and functional pharmacological treatments to improve the health status of patients. However, patients are increasingly sceptical of pharmacological treatments which are often associated with moderate to severe side effects. The aim of our review is to provide a collection of the most recent scientific evidence on the most common phytochemicals, used for centuries in the Mediterranean diet and traditional chinese medicine that act on these key regulators of cholesterol homeostasis and systemic inflammation, which could constitute important tools for CVD management.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 39-53"},"PeriodicalIF":1.4,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of NAFLD-related SNPs on the carotid atherosclerosis development; a five-year prospective observational study","authors":"Hiroaki Ikezaki ,&nbsp;Ryoko Nakashima ,&nbsp;Yuji Matsumoto ,&nbsp;Azusa Ohta ,&nbsp;Sho Yamasaki ,&nbsp;Satoshi Hiramine ,&nbsp;Koji Takayama ,&nbsp;Eiichi Ogawa ,&nbsp;Masayuki Murata ,&nbsp;Norihiro Furusyo ,&nbsp;Jun Hayashi ,&nbsp;Nobuyuki Shimono ,&nbsp;Ernst J. Schaefer","doi":"10.1016/j.athplu.2024.12.003","DOIUrl":"10.1016/j.athplu.2024.12.003","url":null,"abstract":"<div><h3>Background and aims</h3><div>The prevalence of metabolic dysfunction associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a significant public health concern with an increased atherosclerotic cardiovascular disease risk. This study investigates the impact of NAFLD-related single nucleotide polymorphisms (SNPs) on carotid atherosclerosis development in a Japanese population without diabetes, dyslipidemia, and hypertension.</div></div><div><h3>Methods</h3><div>The prospective observational study, part of the Kyushu and Okinawa Population Study (KOPS), included 945 participants (median age 55 [47, 63]) without carotid atherosclerosis, increased alcohol intake, diabetes, dyslipidemia, hypertension, or chronic hepatitis at baseline. NAFLD-related SNPs (<em>GCKR</em>, <em>NCAN</em>, <em>and PNPLA3</em>) were genotyped, and carotid intima-media thickness (cIMT) was measured using ultrasonography. Univariate and multivariate regression analyses were performed to assess the association of NAFLD-related SNPs on newly developed carotid atherosclerosis over five years.</div></div><div><h3>Results</h3><div>After five years, 125 (13.2 %) participants developed carotid atherosclerosis. The <em>NCAN</em> (rs2228603) T allele was associated with a lower incidence rate of carotid atherosclerosis (4.7 % in <em>NCAN</em> CT/TT genotype vs. 13.9 % in CC genotype; p = 0.04), and <em>NCAN</em> T allele carriers exhibited a favorable lipid profile. These associations were not altered by either recruiting area or obese. The <em>GCKR</em> T allele and <em>PNPLA3</em> C allele were associated with low carotid atherosclerosis development rates but were not significant.</div></div><div><h3>Conclusions</h3><div>Our results suggested that some NAFLD-related SNPs may influence atherosclerosis through lipid metabolism among Japanese individuals without metabolic syndrome.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 10-17"},"PeriodicalIF":1.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HDL-associated vitamin D binding protein levels are inversely associated with necrotic plaque burden in psoriasis","authors":"M.P. Playford ,&nbsp;H. Li ,&nbsp;A.K. Dey ,&nbsp;E.M. Florida ,&nbsp;H.L. Teague ,&nbsp;S.M. Gordon ,&nbsp;N.N. Mehta","doi":"10.1016/j.athplu.2024.12.002","DOIUrl":"10.1016/j.athplu.2024.12.002","url":null,"abstract":"<div><h3>Background and aims</h3><div>Vitamin D binding protein (DBP) serves a dual function as a vitamin D carrier and actin scavenger. Free DBP is present in high concentrations in serum, while a smaller pool is bound to lipoproteins like HDL and VLDL. The role of DBP's interaction with lipoproteins remains unclear. Given that HDL has been proposed to have both atheroprotective and anti-inflammatory properties, we sought to compare whether HDL-associated DBP and/or total serum DBP could serve as useful biomarkers for assessing disease severity in psoriasis and cardiovascular disease.</div></div><div><h3>Methods</h3><div>Psoriasis (PSO) patients (N = 83), which were part of a prospective, observational cohort and non-psoriasis (non-PSO) subjects (n = 35) underwent blood collection for HDL purification by liquid chromatography and CCTA scans to assess coronary plaque burden. Serum and HDL-bound DBP levels were measured by ELISA.</div></div><div><h3>Results</h3><div>The psoriasis cohort was middle-aged (mean ± IQR: 50 (38–59), predominantly male (n = 55, 66 %) and had moderate-to-severe skin disease [psoriasis area severity index score, PASI score, med (IQR): 9.6 (6–18.3)]. Consistent with our previous reports, PSO patients had significantly higher Framingham Risk Score (FRS), high sensitivity C-reactive protein (hs-CRP), Body Mass Index (BMI), insulin resistance (HOMA-IR) and total coronary plaque burden, driven by the rupture-prone non-calcified necrotic core. However, while the concentration of serum DBP (S-DBP) between PSO and non-PSO was unchanged (PSO: 177.80 (125.77–250.99) vs non-PSO: 177.74 (104.32–254.04), the concentration of DBP associated with HDL (HDL-DBP) was decreased in psoriatics (PSO μg/ml: 1.38 (0.64–2.75) vs non-PSO: 1.72 (1.18–3.90). Although both S-DBP and HDL-DBP levels showed inverse correlations with a measure of skin disease severity (PASI) (S-DBP, Rho = −0.022 vs HDL-DBP, Rho = −113), only HDL-DBP exhibited an inverse relationship with necrotic plaque burden [Rho −0.226, p = 0.085 vs S-DBP (0.041, p = 0.76)]. This relationship was strengthened after adjusting for traditional cardiovascular risk factors such as age and sex (β = −0.237, p = 0.045), FRS (β = −0.295, p = 0.033) and including biological treatment and HDL-cholesterol (β = −0.213, p = 0.048).</div></div><div><h3>Conclusions</h3><div>In conclusion, we found HDL-DBP levels may better capture the severity of psoriatic disease and association with cardiovascular risk factors than S-DBP.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 32-38"},"PeriodicalIF":1.4,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in patterns and outcomes of dyslipidemic patients with acute coronary syndrome: A tertiary cardiac center registry","authors":"Hesham Taha ,&nbsp;Mohammad Alshehri ,&nbsp;Hossam El-Hosary ,&nbsp;Abdalla Elagha ,&nbsp;Hosam Mahrous ,&nbsp;Mirna Shaker ,&nbsp;Omar Younis ,&nbsp;Mohamed Saad","doi":"10.1016/j.athplu.2024.11.004","DOIUrl":"10.1016/j.athplu.2024.11.004","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 18-24"},"PeriodicalIF":1.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}